Rapid Improvement of Genital Aphthae by Topical FK-506 in

Document Type : Case Report

Authors

1 Assistant Professor, Department of Rheumatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

2 Internist, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Associate Professor, Department of Rheumatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Rheumatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan.

Abstract

Background: Behcet's disease is a chronic, complex multisystemic disease characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmic and gastrointestinal manifestations.   Case report: We describe a 24-year-old woman with recurrent oral and genital aphthae, ophthalmic lesions, pseudofolliculitis lesions in skin of lower limbs, and positive result on pathergy testing. She was treated with methotrexate, azathioprine, prednisolone, folic acid and calcium. Despite using these drugs from 4 months ago, she also was complaining from a genital aphthae (2.8 × 18 mm in diameter) from 30 days before admission affected on gaiting. After using of topical FK-506, genial aphthae resolved after 20 days.

Keywords

References

  1. Dilsen N. History and development of Behçet's disease. Rev Rhum Engl Ed 1996; 63(7-8): 512-9.
  2. Zoubloulis CC. Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne (Paris) 1999; 150(6): 488-98.
  3. Kontogiannis V, Powell RJ. Behçet's disease. Postgrad Med J 2000; 76(900): 629-37.
  4. Davatchi F, Tehrani Banihashemi A, Gholami J, Faezi ST, Forouzanfar MH, Salesi M, et al. The prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR COPCORD study (stage 1, rural study) in Iran. Clin Rheumatol 2009; 28(11): 1267-74.
  5. Rachel A. Behcet's disease. In: Harris E, Budd R, Firestein G, Genovese M, Sergent J, Ruddy S, et al. Kelley's Textbook of Rheumatology. Philadelphia: WB. Saunders; 2005. p. 1396-401.
  6. Moutsopoulos HM Behcet's syndrome. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw-Hill Professional; 2008. p. 2132.
  7. Ghate JV, Jorizzo JL. Behçet's disease and complex aphthosis. J Am Acad Dermatol 1999; 40(1): 1-18; quiz 19-20.
  8. Evereklioglu C. Managing the symptoms of Behçet's disease. Expert Opin Pharmacother 2004; (2): 317-28.
  9. Chams-Davatchi C, Barikbin B, Shahram F, Nadji A, Moghaddassi M, Yousefi M, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. Int J Rheum Dis 2010; 13(3): 253-8.
  10. Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999; 135(5): 529-32.
  11. Lampropoulos CE, Sangle S, Harrison P, Hughes GR, D'Cruz DP. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43(11): 1383-5.
Journal of Isfahan Medical School
Volume 28, Issue 122 - Serial Number 122
November and December 2011
Pages 1820-1824

Files

History

  • Receive Date: 22 November 2010
  • Revise Date: 03 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics